Rate Video

ASCO 2020 | Significance of oral hypomethylating agents

Amer Zeidan • 1 Jun 2020

Acute Myeloid Leukemia Leukemia Myelodysplastic Syndromes Azacitidine Decitabine

Amer Zeidan, MBBS, MHS, of Yale University and Yale Cancer Center, New Haven, CT, highlights the importance of the development of oral hypomethylating agents to improve patient compliance and outcomes. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Cereblon and GSPT1 degrader in refractory/relapsed AML

Amer Zeidan • 12 Jun 2020

Glasdegib in combination with azacitidine in MDS, AML and CMML

Amer Zeidan • 1 Jun 2020

Temporal patterns among older patients with AML

Amer Zeidan • 27 Sep 2019

hypomethylating agents in AML

Amer Zeidan • 1 Jun 2020

Related Videos

Real-world findings of MRD by MFC in AML

Bruno Paiva • 24 Feb 2021

Impact of MMRD and ELN genetic classification in outcomes for patients with AML underoging alloHCT

Muhammad Husnain • 17 Feb 2021

SIERRA trial updates: apamistamab in AML

Tania Jain • 12 Feb 2021

CAR-T vs. BiTEs in B-cell malignancies

Marion Subklewe • 11 Feb 2021